TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
ANGLE plc ( (GB:AGL) ) has provided an update.
ANGLE plc has announced a collaboration with Myriad Genetics to assess the feasibility of using Parsortix-derived circulating tumour cell (CTC) DNA alongside Myriad’s existing tissue-based diagnostic test. This partnership aims to enhance patient treatment by improving access to genomic data through a simple blood test, potentially impacting the precision medicine field significantly.
The most recent analyst rating on (GB:AGL) stock is a Hold with a £5.50 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
Spark’s Take on GB:AGL Stock
According to Spark, TipRanks’ AI Analyst, GB:AGL is a Neutral.
ANGLE plc’s stock score is primarily influenced by ongoing financial challenges, including negative profitability and cash flow issues, which weigh heavily on the score. Despite positive corporate events showcasing innovation and potential growth, bearish technical signals and unattractive valuation metrics limit the overall score.
To see Spark’s full report on GB:AGL stock, click here.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company specializing in innovative circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company’s primary product, the Parsortix® PC1 System, is FDA cleared and enables comprehensive downstream analysis, including whole cell imaging and molecular analysis. ANGLE focuses on diagnostic products and clinical services, offering custom assay development and clinical trial testing.
Average Trading Volume: 1,109,596
Technical Sentiment Signal: Sell
Current Market Cap: £18.55M
See more insights into AGL stock on TipRanks’ Stock Analysis page.